
Chinese clinical stage biotechnology company founded in 2019 at Nanshan in Shenzhen developing mRNA medicines delivered by its own lipid nanoparticle technology, with programmes in rare disease, in vivo immunotherapy, tumour therapeutic vaccines and infectious disease vaccines.
회사 프로필 보기
평가 남기기